Comparative electrophysiological study of response to botulinum toxin type B in Japanese and Caucasians

Movement Disorders

Volumn 23, Issue 2, 2008, Pages 240-245

  Arimura, Kimiyoshi ^a   Arimura, Yumiko ^a   Takata, Yoshiharu ^a   Nakamura, Tomonori ^a   Kaji, Ryuji ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Botulinum toxin type B; Electrophysiology; Extensor digitorum brevis muscle; M wave amplitude

Indexed keywords

BOTULINUM TOXIN B; PLACEBO;

ADULT; ANISOTROPY; ARTICLE; CAUCASIAN; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTROPHYSIOLOGY; EXTENSOR DIGITORUM LONGUS MUSCLE; HUMAN; JAPANESE; MALE; MUSCLE EXCITATION; MUSCLE RELAXATION; PERONEUS NERVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROPHYSIOLOGY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLES; TIME FACTORS;

EID: 39749142092     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21807     Document Type: Article

References (18)

1. Brashear A. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol 2001;21:85-90.
2. Brin MF, Jankovic J, Comella C, Blitzer A, Tsui J, Pulman SL. Treatment of dystonia using botulinum toxin. In: Kurlan R, editor. Treatment of movement disorders. Philadelphia: Lippincott; 1995. p 183-246.
3. Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21.
4. Jankovic J. Botulinum toxin in movement disorders. Curr Opin Neurol 1994;17:358-366.
5. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992;359:832-835.
6. Schiavo G, Santucci A, Dasgupta BR, et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 1993;335:99-103.
7. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
8. Hatheway CL, Dang C. Immunogenicity of the neurotoxins of clostridium botulinum. In: Jankovic L, Hallet M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994. p 93-107.
9. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996;46:26-29.
10. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
11. Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Mov Disord 1997;12:772-775.
12. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-1438.
13. Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 2005;20:1152-1160.
14. Kimura J. Electrodiagnosis in diseases of nerve and muscle: principles and practice, 2nd ed. Philadelphia: F.A. Davis Company; 1989. p 97-98.
15. Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997;49:189-194.
16. Sloop RR, Escutin RO, Matus JA, Cole BA, Peterson GW. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 1996;46:1382-1386.
17. Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 1998;64:577-580.
18. Kohara N, Kimura J, Kaji R, et al. F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicentre analysis in healthy subjects and patients with diabetic polyneuropathy. Diabetologia 2000;43:915-921.